ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts In Phase 1b Trial Of ORIC-114 In Patients With Mutated NSCLC
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations
Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-naïve EGFR exon 20 NSCLC
Expect to report updated Phase 1b data in the first half of 2025